Summary
Persistent hunger while using Retatrutide is more common than most people expect. This article explains the most likely reasons — from dose, timing, and rebound appetite to individual variation — based on what the research shows.
The Short Answer
Persistent hunger on Retatrutide usually comes down to one or more of the following: the dose has not yet reached the effective range for your body weight and metabolic state, the timing of injections relative to meals is not optimised, dietary composition is undermining the satiety signal, or your body is adapting to the compound's appetite effects faster than expected.
None of this means the compound is not working. It means the protocol needs review.
How Retatrutide Suppresses Appetite
Retatrutide is a triple agonist acting on three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). This triple-action mechanism distinguishes it from earlier GLP-1 monotherapies like semaglutide and from dual GLP-1/GIP agents like tirzepatide.
The appetite suppression primarily comes from GLP-1 receptor activation, which:
- Slows gastric emptying, so food stays in the stomach longer and signals fullness for a greater duration
- Acts on hypothalamic satiety centres, reducing the drive to eat
- Modulates reward signalling associated with food
The GIP receptor component may amplify these effects. The glucagon receptor component adds energy expenditure and fat oxidation on top of appetite reduction — which is part of what makes Retatrutide's weight loss signal in trials stronger than dual agonists.
Likely Reasons Hunger Persists
1. You Are Still in the Dose Escalation Phase
The Phase 2 NEJM trial by Jastreboff et al. (2023) found that Retatrutide's most significant appetite and weight effects occurred at higher doses (8 mg and 12 mg weekly), with the escalation protocol taking 24 weeks to reach the target. At lower doses, appetite suppression exists but is milder.
If you are early in a protocol and at a lower dose, this is the most common reason for persistent hunger.
2. Adaptation to the Initial Effect
Like all GLP-1 receptor agonists, the subjective appetite suppression is often most pronounced in the first days at any new dose. As the body adapts over one to two weeks, some of this acute effect diminishes before stabilising. This can feel like the compound has "stopped working" even when it has not.
3. Diet Composition
The satiety effect of GLP-1 receptor agonism is significantly influenced by what you eat. Refined carbohydrates digest quickly and bypass much of the slowed gastric emptying benefit. High-protein, high-fibre meals produce stronger and longer satiety signals because they require more processing and generate stronger gut hormone responses.
If your diet is high in processed foods, you may feel the appetite suppression less reliably.
4. Injection Timing
The peak plasma concentration of Retatrutide occurs roughly 24–48 hours after injection for the weekly formulation. Whether you inject on a specific day relative to your highest-appetite periods (weekends, social eating events) can meaningfully influence subjective experience.
5. Sleep and Stress
Both poor sleep and chronic psychological stress elevate ghrelin (the primary hunger hormone) and reduce leptin sensitivity. GLP-1 receptor agonists do not fully counter these inputs. If sleep quality or stress load has worsened, hunger may increase despite the compound.
6. Individual Variation in Receptor Sensitivity
GLP-1 receptor expression and sensitivity vary between individuals due to genetic polymorphisms. Some people show robust appetite suppression at relatively low doses; others require higher doses to achieve the same effect. This is not a failure of the compound — it reflects biological variation.
What the Research Shows
In the Phase 2 Retatrutide trial, participants receiving 8 mg weekly lost an average of 17.5% of body weight at 48 weeks — significantly more than semaglutide trials. However, the appetite reduction was not uniform: some participants in lower-dose groups reported minimal appetite change early on, while others showed strong responses at the same dose.
Importantly, the trial used a structured dose escalation over 24 weeks specifically because higher doses early produced greater gastrointestinal side effects. The hunger reduction builds as the dose builds.
Questions to Ask Before Adjusting
Before changing a protocol, consider:
- Am I actually at the target dose for my body weight, or still escalating?
- What does my diet look like — predominantly whole foods or processed?
- How is my sleep over the past two to three weeks?
- Has anything changed — stress, travel, medication — that might influence hunger signals?
- How long have I been at this current dose? (Less than two weeks is too early to evaluate)
Related Topics
Safety & Regulatory Note
Retatrutide is an investigational compound. It is not approved as a medical treatment anywhere in the world. This article is for educational purposes only. Any use outside a formal research or clinical context carries unquantified risks.
References
- 1.Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist Retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526.
- 2.Drucker DJ. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351.
- 3.Nauck MA, Wefers J, Meier JJ. (2021). Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes & Endocrinology, 9(8), 525–544.
